Previous close | 3.0800 |
Open | 3.6500 |
Bid | 4.1000 |
Ask | 5.1000 |
Strike | 62.50 |
Expiry date | 2024-06-21 |
Day's range | 3.6500 - 4.3000 |
Contract range | N/A |
Volume | |
Open interest | 120 |
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
REDWOOD CITY, Calif. & SANTA MONICA, Calif., May 09, 2024--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder.
Unraveling the Financial Dynamics and Strategic Directions of Gilead Sciences Inc (GILD)